Hepalab Tablet is a pharmaceutical formulation containing L-Ornithine L-Aspartate (150 mg) and Pancreatin (100 mg), designed to support hepatic function and improve digestive enzyme activity. L-Ornithine L-Aspartate is an amino acid compound that plays a critical role in ammonia detoxification by enhancing the urea cycle, thereby reducing elevated blood ammonia levels commonly observed in hepatic encephalopathy and chronic liver diseases. Pancreatin, a mixture of digestive enzymes including amylase, lipase, and protease, aids in the digestion and absorption of nutrients by compensating for pancreatic insufficiency. Hepalab Tablet is indicated for patients with liver dysfunction, hepatic encephalopathy, and exocrine pancreatic insufficiency, where it helps restore metabolic balance and improve gastrointestinal symptoms such as indigestion, bloating, and malabsorption. The combined action of L-Ornithine L-Aspartate and Pancreatin facilitates detoxification, enhances protein metabolism, and promotes efficient digestion. This medication should be used under medical supervision, considering contraindications such as hypersensitivity to any component and caution in patients with severe renal impairment. Dosage and duration of therapy should be individualized based on clinical response and patient condition. Hepalab Tablet offers a synergistic approach to managing hepatic and pancreatic insufficiencies, contributing to improved patient outcomes.